Skip Navigation



JAC Advance Access published online on December 8, 2004

Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkh501
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
55/1/95    most recent
dkh501v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Marra, F.
Right arrow Articles by Hutchinson, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Marra, F.
Right arrow Articles by Hutchinson, J. M.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

JAC © The British Society for Antimicrobial Chemotherapy 2004; all rights reserved
Received March 15, 2004
Revised September 30, 2004
Accepted October 14, 2004

Original article

Effect of formulary policy decisions on antimicrobial drug utilization in British Columbia

Fawziah Marra 1*, David M. Patrick 2, Rick White 3, Helen Ng 3, William R. Bowie 4, and James M. Hutchinson 5

1 Faculty of Pharmaceutical Sciences, Department of Medicine, Vancouver Hospital and Health Sciences Centre, University of British Columbia, Vancouver Canada; Vaccine and Pharmacy Services, BC Centre for Disease Control, 655 West 12th Avenue, Vancouver BC, V5Z 4R4, Canada
2 Communicable Disease Epidemiology, BC Centre for Disease Control, 655 West 12th Avenue, Vancouver BC, V5Z 4R4, Canada; Health Care and Epidemiology, Department of Medicine, Vancouver Hospital and Health Sciences Centre, University of British Columbia, Vancouver; Canada
3 Communicable Disease Epidemiology, BC Centre for Disease Control, 655 West 12th Avenue, Vancouver BC, V5Z 4R4, Canada
4 Division of Infectious Diseases, Department of Medicine, Vancouver Hospital and Health Sciences Centre, University of British Columbia, Vancouver, Canada
5 Department of Microbiology, Memorial University of Newfoundland Health Sciences Centre, St. John's, NF, Canada

* To whom correspondence should be addressed.
Fawziah Marra, E-mail: fawziah.marra{at}bccdc.ca


   Abstract

Background: Formularies are used routinely for management of drug expenditures yet evaluations of their impact remain rare. The objective of this study was to analyse the impact of addition or deletion of antimicrobials from the provincial formulary on drug utilization.

Methods: We obtained data from the British Columbia PharmaNet database on all outpatient oral antimicrobial prescriptions from 1996 to 2000 and converted them to their defined daily dose (DDD) equivalents according to the ATC system. Trends in utilization associated with a changing formulary status of new antimicrobial agents were analysed. Maximum likelihood estimation was used to determine the rate of increase in utilization resulting from addition to the formulary. Models were adjusted for seasonal and temporal trends as well as serial correlation.

Results: During this time period, clarithromycin was on formulary, later delisted, and then relisted again. Valaciclovir and famciclovir were also added to the formulary. During the time clarithromycin was off the formulary, the rate of change in its monthly consumption was 0.0061 DDD/1000 population/day; following its relisting, the rate of change increased by 818% to 0.0560 DDD/1000 population/day (P=0.002). After the listing of valaciclovir on the formulary, the rate of change in its monthly consumption increased 57% from a baseline of 0.0014 to 0.0022 DDD/1000 population/day (P=0.07). A similar effect was seen with the addition of famciclovir to the formulary whereby the rate of change in monthly consumption increased from 0.0008 (before addition to the formulary) to 0.0018 (after addition to the formulary) (P ≤ 0.001).

Conclusions: Listing of antimicrobials on provincial or countrywide formularies is followed temporally with increased utilization. However, before governmental agencies can institute reference-based pricing or co-payment programmes, the effect of such a programme on the emergence of antimicrobial resistance and on patient outcomes needs further study.

Keywords: antimicrobial consumption; macrolides; clarithromycin; valaciclovir; famciclovir.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
CMAJHome page
D. M. Patrick MD MHSc and J. Hutchinson MD
Antibiotic use and population ecology: How you can reduce your "resistance footprint"
Can. Med. Assoc. J., February 17, 2009; 180(4): 416 - 421.
[Full Text] [PDF]


Home page
The Annals of PharmacotherapyHome page
F. Marra, D. L Monnet, D. M Patrick, M. Chong, C. T Brandt, M. Winters, M. S Kaltoft, G. J Tyrrell, M. Lovgren, and W. R Bowie
A Comparison of Antibiotic Use in Children Between Canada and Denmark
Ann. Pharmacother., April 1, 2007; 41(4): 659 - 666.
[Abstract] [Full Text] [PDF]


Home page
J Antimicrob ChemotherHome page
F. M. MacKenzie, D. L. Monnet, I. M. Gould, and on behalf of the ARPAC Steering Group
Relationship between the number of different antibiotics used and the total use of antibiotics in European hospitals
J. Antimicrob. Chemother., September 1, 2006; 58(3): 657 - 660.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.